DBV Technologies SA – (NASDAQ:DBVT) has earned an average rating of “Buy” from the six research firms that are currently covering the firm. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $47.00.

Several analysts recently weighed in on DBVT shares. Zacks Investment Research upgraded DBV Technologies SA – from a “hold” rating to a “buy” rating and set a $38.00 price objective for the company in a report on Thursday, January 19th. Natixis upgraded DBV Technologies SA – from a “neutral” rating to a “buy” rating in a report on Friday, February 17th. Societe Generale upgraded DBV Technologies SA – from a “hold” rating to a “buy” rating in a report on Thursday, March 16th. Jefferies Group LLC restated a “buy” rating and issued a $47.00 price objective on shares of DBV Technologies SA – in a report on Thursday, March 16th. Finally, Leerink Swann restated an “outperform” rating on shares of DBV Technologies SA – in a report on Wednesday, March 15th.

DBV Technologies SA – (NASDAQ:DBVT) traded up 1.31% during mid-day trading on Friday, hitting $34.77. 125,395 shares of the stock were exchanged. The stock’s market cap is $1.60 billion. DBV Technologies SA – has a 52-week low of $27.02 and a 52-week high of $37.98. The stock has a 50 day moving average of $34.26 and a 200-day moving average of $35.10.

Institutional investors have recently bought and sold shares of the stock. Sphera Funds Management LTD. raised its position in DBV Technologies SA – by 30.4% in the third quarter. Sphera Funds Management LTD. now owns 79,058 shares of the company’s stock valued at $2,872,000 after buying an additional 18,447 shares during the period. Great Point Partners LLC bought a new position in DBV Technologies SA – during the third quarter valued at about $4,776,000. OLD Mission Capital LLC bought a new position in DBV Technologies SA – during the third quarter valued at about $2,207,000. Baker BROS. Advisors LP bought a new position in DBV Technologies SA – during the third quarter valued at about $200,162,000. Finally, Acuta Capital Partners LLC raised its position in DBV Technologies SA – by 63.3% in the fourth quarter. Acuta Capital Partners LLC now owns 91,898 shares of the company’s stock valued at $3,228,000 after buying an additional 35,638 shares during the period. Institutional investors own 48.96% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/05/19/dbv-technologies-sa-dbvt-receives-consensus-recommendation-of-buy-from-analysts.html.

About DBV Technologies SA –

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

5 Day Chart for NASDAQ:DBVT

Receive News & Ratings for DBV Technologies SA - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA - and related companies with MarketBeat.com's FREE daily email newsletter.